Welcome: Guest | Register | Login |

Aldevron Receives Growth Investment from TA Associate

Awardee Story Aldevron Receives Growth Investment from TA Associate
Date: Jan 24, 2017

Source: FinSMEs ( click here to go to the source)

Aldevron, a Fargo, North Dakota-based contract development and manufacturing organization specializing in the production of plasmid DNA, proteins and antibodies, received a growth investment from TA Associates.

The amount of the deal was not disclosed. Following the deal, Aldevron's management, led by Michael Chambers, CEO, will retain a significant portion of ownership in and will continue to run the company. In conjunction with the funding, Ethan K. Liebermann, a Principal at TA Associates, and Mark H. Carter, a Managing Director at TA Associates, will join the Aldevron Board of Directors.

The company intends to use the funds to increase its manufacturing capabilities and capacity, and advance its R&D ongoing efforts.

Founded in 1998, Aldevron manufactures biologics for research, clinical and diagnostic applications. The company's products are used to manufacture novel treatments for a wide range of indications, including cancer, infectious disease, pediatric disorders and rare diseases.
The company also has additional facilities in Madison, Wisconsin and Freiburg, Germany.



Contact information

Innovation Development Institute, LLC

   45 Beach Bluff Avenue, Suite 300
     Swampscott,  MA 01907-1542

  Tel:  (781) 595-2920